Archives by
Month/Year
September/October 2011 – Hepatitis C treatment costs expected to double
October 2011
IN THIS ISSUE...FEATURE: Breakthrough in the treatment of hepatitic C: treatment costs expected to more than double...Aspirin Falling Out of Favour?...NOC Watch: OxyNEO, Staxyn...Toromont Industries Recognized as a Finalist for the Inaugural Benefits Canada Drug Plan Management Award. View post
Breakthrough in the treatment of hepatitis C: treatment costs expected to more than double
October 2011
Two new oral protease inhibitors have been approved for the treatment of chronic hepatitis C: Incivek (telaprevir) and Victrelis (boceprevir). These drugs are considered breakthrough treatments for hepatitis C, offering a higher cure rate when added to peginterferon alfa and ribavirin – View post
Aspirin Falling Out of Favour?
October 2011
The first Canadian antiplatelet guidelines have been released, and interestingly, they recommend against using aspirin for routine primary prevention of heart attack or stroke in healthy patients. It would appear that the cardiovascular benefits from daily consumption of aspirin are very small View post
NOC Watch – OxyNEO, Staxyn
October 2011
OxyNEO® (oxycodone) OxyNEO® is a new extended-release formulation of OxyContin® released by Purdue Pharma that has been designed to be more difficult to tamper with (i.e. from being cut, broken, chewed, crushed or dissolved) to extract the drug for illicit purposes. This View post
Toromont Industries Recognized as a Finalist for the Inaugural Benefits Canada Drug Plan Management Award
October 2011
Cubic Health is very pleased to announce that one of our clients, Toromont Industries Ltd, has been announced as a Finalist for the inaugural Benefits Canada Drug Plan Management Award that is part of the Workplace Health and Benefits Awards. View post
Latest News
-
N.S. tightens rules on OxyContin -Globe and Mail (February 20, 2012) - Provinces become proactive after being accused of inaction in the face of rising addiction rates - Nova Scotia has become the latest... View post
-
Another Blockbuster Falls: Generic Plavix® Now Available - February 2012 - After over 8 years of patent challenges between the Canadian generic manufacturing company Apotex and the product’s innovator, sanofi-aventis, clopidogrel (generic for... View post
-
Protecting Your Plan from the Gravy Train - February 2012 - Although full-product direct-to-consumer advertising (DTCA) is illegal in Canada, most Canadians are exposed to this type of advertising through media spillage from... View post
-
Many Canadians can’t afford to take drugs as directed -Globe and Mail (January 17, 2012) - One in four Canadians who do not have drug insurance are unable to afford to take their prescription drugs as directed, a... View post
-
Look ahead with predictive modelling -Benefits Canada (January 2012) - The most recent 24 months of data is one of the most important pieces of information that plan sponsors and advisors have... Download PDF
-
Drug Plans Erode Over Last 20 Years -Benefits and Pensions monitor (December 2011) - All of us involved in the provision and management of drug plan benefits should be embarassed by the lack of progress over... Download PDF
-
Are we in 2002 or 2012? A word of caution about mail-order pharmacies -Benefits Canada (November 2011) - If a plan design does not support mail order (or any other preferred pharmacy arrangement) in a meaningful way, it will be... Download PDF
Connect
